Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

Understanding CAR T-Cell Therapy: Guidance for Current Clinic and Future Directions

Credits Available
Pharmacists: 1.0 contact hour (0.1 CEUs)
Released: September 28, 2021 Expiration: September 27, 2022
Start Activity
Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by an educational grant from
Bristol-Myers Squibb
Craig Freyer, PharmD
Zahra Mahmoudjafari, PharmD, BCOP, DPLA

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Review the biologic principles underlying CAR T-cell therapy, structure, and function of the CAR and the mechanism of action of CAR T-cells
  • Identify characteristics of patients who are candidates appropriate for treatment with CAR T-cell therapy
  • Provide safe and effective patient care services through an understanding of the clinical trial data on CAR T-cell–based therapies used to treat patients with leukemia or B-cell lymphomas, myeloma, or chronic lymphocytic leukemia

Information on this Educational Activity

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Faculty

Craig Freyer, PharmD

Clinical Pharmacy Specialist
Hematology/Oncology, Stem Cell Transplant, and Cellular Therapy
Department of Pharmacy
Hospital of the University of Pennsylvania
Philadelphia, Pennsylvania

Craig W. Freyer, PharmD, has disclosed that he has received consulting fees from Astellas, EUSA Pharma, Incyte, and Servier and fees for non-CME/CE services from Astellas.
Zahra Mahmoudjafari, PharmD, BCOP, DPLA

Clinical Pharmacy Manager, Blood and Marrow Transplant Program
Division of Hematological Malignancies and Cellular Therapeutics
PGY2 Oncology Residency Program Director
The University of Kansas Cancer Center
Westwood, Kansas

Zahra Mahmoudjafari, PharmD, BCOP, DPLA, has disclosed that she has received consulting fees from Bristol-Myers Squibb, Coherus, GlaxoSmithKline, Incyte, Medexus, Merck, Novartis, and Omeros.

Staff

Ryan P. Topping, PhD

Scientific Director

Ryan P. Topping, PhD, has no relevant conflicts of interest to report
Megan Cartwright, PhD

Senior Clinical Editor

Megan Cartwright, PhD, has no relevant conflicts of interest to report.
Timothy A. Quill, PhD

Associate Director, Scientific Services

Timothy A. Quill, PhD, has no relevant conflicts of interest to report.
June Wasserstrom

Director, CME Program Development

June Wasserstrom has no relevant conflicts of interest to report.
Kevin Obholz, PhD

Senior Director, Educational Strategy

Kevin Obholz, PhD, has no relevant conflicts of interest to report.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Target Audience

This educational program is intended for managed care and specialty pharmacy professionals and other healthcare providers who care for patients with hematologic malignancies.

Goal

The goal of this activity is to improve the knowledge, competence, and performance of managed care and specialty pharmacy professionals and other healthcare professionals to confidently and competently integrate CAR T-cell therapy into their clinical practices.

Continuing Pharmacy Education

Credit Designation

CCO designates this continuing education activity for 1.0 contact hours (0.10 CEUs) of the Accreditation Council for Pharmacy Education. Universal Activity Number - JA4008176-0000-21-190-H01-P.

Type of Activity: Knowledge

Upon successfully completing the post-test with a score of 65% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.

Program Medium

This program has been made available online.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 1.0 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from September 28, 2021, through September 27, 2022:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Understanding CAR T-Cell Therapy: Guidance for Current Clinic and Future Directions

Loading...
Watch this interactive webcast of a live CCO webinar tailored to managed care and specialty pharmacy professionals to gain expert perspectives on pharmacy fundamentals of CAR T-cell therapy.
Craig Freyer, PharmD
Zahra Mahmoudjafari, PharmD, BCOP, DPLA
Pharmacists: 1.0 contact hour (0.1 CEUs)
Released: September 28, 2021 Expiration: September 27, 2022

Related Content

On-demand webcast of live webinar: Multidisciplinary experts on the care of patients with lymphomas during COVID-19, from Clinical Care Options (CCO)

John Allan, MD Sandra E. Kurtin, PhD, ANP-C, AOCN Physicians: maximum of 0.75 AMA PRA Category 1 Credits Registered Nurses: 0.75 Nursing contact hours Pharmacists: 0.75 contact hours (0.075 CEUs) Released: October 19, 2021 Expired: October 18, 2022

Download this expert-authored resource on current treatment algorithms for MDS from Clinical Care Options (CCO)

Jamile Shammo, MD, FASCP, FACP Released: October 18, 2021

Download this short slideset from Clinical Care Options (CCO) on recent advances in the treatment of systemic amyloidosis.

Beth Faiman, PhD, MSN, APRN-BC, AOCN Shaji K. Kumar, MD Released: October 18, 2021

Sagar Lonial, MD; Suzanne Lentzsch, MD, PhD; and Thomas G. Martin, MD discuss the use of BCMA-targeted agents in relapsed/refractory multiple myeloma in an on-demand webcast, from Clinical Care Options (CCO)

Sagar Lonial, MD
Program Director
Suzanne Lentzsch, MD, PhD Thomas G. Martin, MD
Physicians: maximum of 1.5 AMA PRA Category 1 Credits Released: October 15, 2021 Expired: October 14, 2022
Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by an educational grant from
Bristol-Myers Squibb

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue